Log in

arizona asthma coalition

GSK’s asthma drug shows promise in reducing severe attacks

June 10, 2024 10:25 AM | AAC (Administrator)

Shared from WSAU/Reuters

GSK’s asthma drug met its primary goal of reducing asthma attacks over a 52-week period in a late-stage trial, the British drugmaker said on Tuesday. The drug, called Depemokimab, has the potential to be the first approved ultra-long-acting biologic with a six-month dosing schedule for patients with severe asthma, GSK said in a statement.

Read more

About the Coalition

As a nonprofit partnership since 1996, AAC has worked together with concerned stakeholders including public health, environmental quality, managed care, education, individual physicians and nurses, hospitals, foundations, families and other colleagues.



Arizona Asthma Coalition

Attn: Andrew Arthur, MD

839 W. Congress St.

Tucson, AZ 85745

Copyright © 2018. Arizona Asthma Coalition.

Powered by Wild Apricot Membership Software